HOME
SEARCH
RSS FEED
SUBSCRIBE
Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets
Case ID:
TAB-2488
Web Published:
12/6/2022
Description:
There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Antimalarial_Inhibitors_that_Target_ the_Plasmodial_Surface_Anion_Channel_(PSAC)_Protein_and_Development_of_the_P SAC_Protein_as_Vaccine_Targets
Category(s):
Collaboration
Vaccines
Infectious Disease
Bookmark this page
Download as PDF
For Information, Contact:
Peter Tung
Technology Development Specialist
NIH Technology Transfer
240-669-5483
peter.tung@nih.gov
Inventors:
Sanjay Desai
Keywords:
Anion
ANTIMALARIAL
CHANNEL
DC2XXX
DCXXXX
DXXXXX
Plasmodial
Surface
TARGET
THERAPY
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum